Patents Examined by Changhwa J. Cheu
  • Patent number: 9863965
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 9, 2018
    Assignee: Zora Biosciences OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Patent number: 9850547
    Abstract: A system, device, and method for rapid detection of analytes that includes a living, engineered biosensor cell that is typically a component of the mammalian immune system; a reporter protein that is engineered into and expressed by the living, engineered biosensor cell, wherein the reporter protein emits a detectable signal in response to certain predetermined changes in the cytosol of the living, engineered cell; a signal transduction pathway expressed by the living, engineered biosensor cell, wherein the signal transduction pathway controls a biological process within the cytosol of the living, engineered biosensor cell, and wherein the biochemical process, when it occurs, causes the reporter protein to emit a detectable signal; at least one type of detector molecule that is adapted to bind to a specific analyte; at least one analyte that binds to the detector molecule that is specific to that analyte; a plurality of non-antibody signal transducing elements that are either expressed by the living, engineer
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: December 26, 2017
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Lingchun Zeng, Srikanth Vedamoorthy, Joel S. Lwande, Joseph D. Kittle, Min Mo
  • Patent number: 9850546
    Abstract: A system, device, and method for rapid detection of analytes that includes a living, engineered biosensor cell that is typically a component of the mammalian immune system; a reporter protein that is engineered into and expressed by the living, engineered biosensor cell, wherein the reporter protein emits a detectable signal in response to certain predetermined changes in the cytosol of the living, engineered cell; a signal transduction pathway expressed by the living, engineered biosensor cell, wherein the signal transduction pathway controls a biological process within the cytosol of the living, engineered biosensor cell, and wherein the biochemical process, when it occurs, causes the reporter protein to emit a detectable signal; at least one type of detector molecule that is adapted to bind to a specific analyte; at least one analyte that binds to the detector molecule that is specific to that analyte; a plurality of non-antibody signal transducing elements that are either expressed by the living, engineer
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: December 26, 2017
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Lingchun Zeng, Srikanth Vedamoorthy, Joel S. Lwande, Joseph D. Kittle, Min Mo
  • Patent number: 9850548
    Abstract: A system, device, and method for rapid detection of analytes that includes a living, engineered biosensor cell that is typically a component of the mammalian immune system; a reporter protein that is engineered into and expressed by the living, engineered biosensor cell, wherein the reporter protein emits a detectable signal in response to certain predetermined changes in the cytosol of the living, engineered cell; a signal transduction pathway expressed by the living, engineered biosensor cell, wherein the signal transduction pathway controls a biological process within the cytosol of the living, engineered biosensor cell, and wherein the biochemical process, when it occurs, causes the reporter protein to emit a detectable signal; at least one type of detector molecule that is adapted to bind to a specific analyte; at least one analyte that binds to the detector molecule that is specific to that analyte; a plurality of non-antibody signal transducing elements that are either expressed by the living, engineer
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: December 26, 2017
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Lingchun Zeng, Srikanth Vedamoorthy, Joel S. Lwande, Joseph D. Kittle, Min Mo
  • Patent number: 9841431
    Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: December 12, 2017
    Assignee: ZORA BIOSCIENCES OY
    Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
  • Patent number: 9839380
    Abstract: A method for generating correlations between human biological phenotype and human behavioral and/or emotional phenotype, and optionally to temporal location, comprising the steps of correlating data on biological phenotype with survey-based data on behavioral and/or emotional phenotype. The data on biological phenotype is collected from a sample from an individual, and the survey-based data can be collected from answers to behavioral and emotional questions from the individual or from observations of the individual by a third party. Correlations can further be used to predict behavior, including preferences, wellness needs and desires, and/or emotions. Feedback, advice and guidance can be provided to individuals based on such correlations. Such correlations are further useful for product and service providers and industries for purposes of standardizing or rating product quality and efficacy, and/or for promotion and selling purposes.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: December 12, 2017
    Assignee: IPHENOTYPE LLC
    Inventors: Jay M. Short, Steve Briggs
  • Patent number: 7514223
    Abstract: The invention is directed to a cross-screening system and methods of the invention utilizing a combination of an immunoassay (IA) and electrochemiluminescence assay (ECLA) to identify molecules that have binding affinities for a target molecule. The cross-screening system and methods of the invention can detect molecules that have binding affinities for the target molecule below the detection limits of the individual immunoassay or ECLA. The cross-screening system and methods of the invention are useful for generating a pool of candidate analyte molecules enriched in a desired characteristic, such as low binding affinity for a target molecule. Low affinity antibodies identified by the cross-screening system and methods of the invention are useful, for example, in assessing the safety and efficacy of biological therapeutics.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: April 7, 2009
    Assignee: Genentech, Inc.
    Inventors: Jihong Yang, Valerie Elizabeth Quarmby
  • Patent number: 7494780
    Abstract: The present invention relates to the discovery that an epididymis-specific defensin, EP2D, plays an important role in regulating sperm motility and therefore male fertility. Provided are methods for evaluating male fertility based on the level of EP2D bound to sperm, kits for evaluating male fertility, and methods for enhancing or suppressing fertility in a male by regulating the level of EP2D and the binding between sperm and EP2D.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: February 24, 2009
    Assignee: The Chinese University of Hong Kong
    Inventors: Hsiao Chang Chan, Chenxi Zhou, Chuen Pei Ng, Yiu Wa Chung
  • Patent number: 7459276
    Abstract: The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: December 2, 2008
    Assignee: Scantibodies Laboratory, Inc.
    Inventors: Thomas L. Cantor, Ping Gao
  • Patent number: 7455976
    Abstract: A complex having oxLDL bound covalently to ?2-GPI can be used as a standard for measuring a ?2-GPI/oxLDL complex in the living body thereby measuring the ?2-GPI/oxLDL complex in the living body more accurately and strictly, and can be utilized to provide a new measurement method, detection method, kit etc.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: November 25, 2008
    Inventor: Eiji Matsuura
  • Patent number: 7455979
    Abstract: The invention provides a method for the structural analysis of a saccharide, comprising: a) providing on a surface a plurality of essentially sequence- and/or site-specific binding agents; b) contacting said surface with a saccharide to be analyzed, or with a mixture comprising a plurality of fragments of said saccharide; c) washing or otherwise removing unbound saccharide or saccharide fragments; d) adding to the surface obtained in step c) an essentially sequence- and/or site-specific marker, or a mixture of essentially sequence- and/or site-specific markers; e) acquiring one or more images of the markers that are bound to said surface; and f) deriving information related to the identity of the saccharide being analyzed from said image.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: November 25, 2008
    Assignee: Procognia Ltd.
    Inventor: Ofer Markman
  • Patent number: 7442774
    Abstract: An antibody is provided which specifically recognizes and binds to INGAP protein. The antibody is used in competitive binding assays for quantitation of INGAP in biological samples. The assay can be performed on a solid support or in a suspension.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: October 28, 2008
    Assignee: GMP Endotherapeutics, Inc.
    Inventors: Aaron I. Vinik, David A. Taylor-Fishwick
  • Patent number: 7413906
    Abstract: In proteomic research, it is often necessary to screen a large number of polypeptides for the presence of stable structure. Described herein are methods (referred to as MALDI MS-HX and SUPREX) for measuring the stability of proteins in a rapid, high-throughput fashion. The method employs hydrogen exchange to estimate the stability of quantities of unpurified protein extracts, using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. A method of quantitatively determining the stability of a test protein under native conditions is disclosed.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 19, 2008
    Assignee: Duke University
    Inventors: Terence G. Oas, Sina Ghaemmaghami, Kendall D. Powell, Michael C. Fitzgerald
  • Patent number: 7407764
    Abstract: This invention provides the first blood test which characterizes asthma severity. More specifically, the present invention provides methods of determining the severity of acute asthma in a patient by determining the levels of C5a or C5a-desArg in the patient's blood, plasma or serum.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: August 5, 2008
    Assignee: The Research Foundation of State University of New York
    Inventors: Rauno Joks, Hazel P. Drew, Myrelle B. Castro, Nandita Mathur Khaneja
  • Patent number: 7138247
    Abstract: Compositions and methods for detection of the stress-inducible Hsp70B? protein are disclosed. These include antibodies directed against particular amino acid regions of Hsp70B? and various peptides corresponding, or antigenically equivalent, to the regions. The ability to generate anti-Hsp70B? antibodies to defined epitopes permits a variety of in vitro and in vivo uses.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: November 21, 2006
    Assignee: Stressgen Biotechnologies Corporation
    Inventors: Heather A. Boux, Geraldine S. Wong, Henry Rodriguez
  • Patent number: 6887689
    Abstract: The present invention refers to a biosensor in which an immobolized carbohydrate or a derivative thereof is used to generate a detectable signal when a protein, a virus or a cell is bound to the carbohydrate surface. The sensor is an optical sensor, a piezoelectric sensor, an electrochemical electrode or a thermistor. A method of binding carbohydrates to a gold surface is also described.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: May 3, 2005
    Inventors: Kurt Nilsson, Carl-Fredrik Mandenius
  • Patent number: 6869770
    Abstract: Pregnancy-associated glycoproteins (PAGs) are structurally related to the pepsins, thought to be restricted to the hoofed (ungulate) mammals and characterized by being expressed specifically in the outer epithelial cell layer (chorion/trophectoderm) of the placenta. By cloning expressed genes from ovine and bovine placental cDNA libraries, the inventors estimate that cattle, sheep, and most probably all ruminant Artiodactyla, possess possibly 100 or more PAG genes, many of which are placentally expressed. The PAGs are highly diverse in sequence, with regions of hypervariability confined largely to surface-exposed loops. Selected PAG that are products of the iOnvasive binucleate cells, expressed highly in early pregnancy at the time of trophoblast invasion and expressed weakly, if at all, in late gestation are useful in the early diagnosis of pregnancy. In a preferred embodiment, the invention relates to immunoassays for detecting these PAGs.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: March 22, 2005
    Assignee: The Curators of the University of Missouri
    Inventors: Robert Michael Roberts, Jonathan Andrew Green, Sancai Xie
  • Patent number: 6828109
    Abstract: The present invention relates to methods of staining cells for flow cytometry, using catalyzed reporter deposition and amplification staining. A catalyzed reporter deposition or an analyte dependent enzyme activation system is described for detecting and/or quantitating an analyte of interest in or on a cell by flow cytometry. Also described are compositions for use in catalyzed reporter deposition methods that can be used to reduce background staining, and thereby enhance peak signal separation between histograms obtained from cells stained with control immunoglobulin versus cells stained with immunoglobulin specific for an analyte of interest, in catalyzed deposition methods.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: December 7, 2004
    Inventor: David R. Kaplan
  • Patent number: 6828106
    Abstract: The present invention relates to a polypeptide multimer comprising a first polypeptide having associated therewith a label and a second polypeptide, wherein a) at least one of the polypeptides is susceptible to protease digestion; b) association of the polypeptides to form a multimer is detectable via a signal emitted by the label; and c) digestion of at least one polypeptide results in dissociation of the multimer and modulation of the signal emitted by the label, and The method of detecting or monitoring the activity of a protease enzyme based on such a multimer.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: December 7, 2004
    Assignee: Cyclacel Limited
    Inventors: John Colyer, Joanne Lightowler
  • Patent number: 6824989
    Abstract: A purified or highly pure recombinant monoclonal antibody with 4G10-hybridoma type specificity is disclosed along with polynucleotides, including cDNA sequences, encoding the antibody chains and the amino acid sequences corresponding to said cDNA polynucleotides and uses for said sequences. Also disclosed are corresponding tagged sequences useful in molecular biological techniques and uses for said sequences.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: November 30, 2004
    Assignee: Upstate Biotechnology, Inc.
    Inventors: Dominic Eisinger, Lynn Stiles, Arthur LaMarche, Thomas Jelinek